Latest & greatest articles for azithromycin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on azithromycin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on azithromycin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for azithromycin

1. Effect of Once-Weekly Azithromycin vs Placebo in Children With HIV-Associated Chronic Lung Disease: The BREATHE Randomized Clinical Trial Full Text available with Trip Pro

Effect of Once-Weekly Azithromycin vs Placebo in Children With HIV-Associated Chronic Lung Disease: The BREATHE Randomized Clinical Trial Effect of Once-Weekly Azithromycin vs Placebo in Children With HIV-Associated Chronic Lung Disease: The BREATHE Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 (...) in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Randomized Controlled Trial JAMA Netw Open Actions . 2020 Dec 1;3(12):e2028484. doi: 10.1001/jamanetworkopen.2020.28484. Effect of Once-Weekly Azithromycin vs Placebo in Children With HIV-Associated Chronic Lung Disease

2021 EvidenceUpdates

2. Hydroxychloroquine vs. azithromycin for hospitalized patients with COVID-19 (HAHPS): results of a randomized, active comparator trial Full Text available with Trip Pro

Hydroxychloroquine vs. azithromycin for hospitalized patients with COVID-19 (HAHPS): results of a randomized, active comparator trial CDEI - Hydroxychloroquine vs. azithromycin for hospitalized patients with COVID-19 (HAHPS): results of a randomized, active comparator trial — CDEI Open Menu Close Menu Open Menu Close Menu Nov 17 Written By Citation: Brown, S. M. , Peltan, I., Kumar, N., Leither, L., Webb, B. J., Starr, N., . . . Greene, T. (2020). Hydroxychloroquine vs. azithromycin (...) patients. Azithromycin 500mg once on day 1, then 250mg once daily for 4 days. Outcomes: Primary outcomes: COVID Ordinal Outcomes Scale on Day 14 (1= home without limitations on usual activities, to 8=death). Hydroxychloroquine was not shown to result in a less favorable COVID Ordinal Outcome at 14 days OR = 1.07 (95% CI 0.63-1.83) Secondary and safety outcomes: No significant difference between hydroxychloroquine and azithromycin groups in hospital free, ventilator free, and ICU free days censored

2020 Covid-19 Drug Evidence Initiative

3. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19 Full Text available with Trip Pro

Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19 CDEI - Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19 — CDEI Open Menu Close Menu Open Menu Close Menu Dec 13 Written By Citation: Omrani, A. S. , Pathan, S. A., Thomas, S. A., Harris, T. R., Coyle, P. V., Thomas, C. E., ... & Elmalik, A. (2020). Randomized (...) double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine , 29 , 100645. DOI: Clinical trial registry link : Full PICO and Limitations in text: Population: 456 non-hospitalized adult (>18 years) patients diagnosed with PCR-confirmed SARS-CoV-2 infection and with no to mild symptoms. Interventions and Comparator Intervention: 152 patients. Hydroxychloroquine (HCQ) with placebo - Hydroxychloroquine 200mg q8h

2020 Covid-19 Drug Evidence Initiative

4. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Full Text available with Trip Pro

Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. The efficacy and safety of azithromycin in the treatment of COVID-19 remain uncertain. We assessed whether adding azithromycin to standard of care, which included hydroxychloroquine, would improve clinical outcomes of patients admitted to the hospital with severe COVID-19.We did an open-label (...) , randomised clinical trial at 57 centres in Brazil. We enrolled patients admitted to hospital with suspected or confirmed COVID-19 and at least one additional severity criteria as follows: use of oxygen supplementation of more than 4 L/min flow; use of high-flow nasal cannula; use of non-invasive mechanical ventilation; or use of invasive mechanical ventilation. Patients were randomly assigned (1:1) to azithromycin (500 mg via oral, nasogastric, or intravenous administration once daily for 10 days) plus

2020 Lancet

5. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial Full Text available with Trip Pro

Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial CDEI - Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial — CDEI Open Menu Close Menu Open Menu Close Menu Sep 6 Written By Note: Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media (...) as established information (medRxiv). Citation: Sekhavati, E. , Jafari, F., Seyedalinaghi, S., Siahkali, S. J., Sadr, S., Tabarestani, M., … Ghiasvand, F. (2020). Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents, 106143. DOI: Full PICO and Limitations in text: Population: 111 hospitalized patients (≥18 years) with positive RT-PCR test and compelling clinical symptoms including radiographic imaging of COVID-19

2020 Covid-19 Drug Evidence Initiative

6. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis Full Text available with Trip Pro

Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) . 2020 Aug 26;S1198-743X(20)30505-X. doi: 10.1016/j.cmi.2020.08.022. Online ahead of print. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis , , , , , Affiliations Expand Affiliations 1 CESP (Centre for Research in Epidemiology and Population Health), Faculté de Médecine-Université Paris-Sud, Faculté de Médecine-UVSQ, INSERM, Université Paris Saclay, Villejuif, France; Gustave Roussy

2020 EvidenceUpdates

7. Hydroxychloroquine with or without azithromycin in mild-to-moderate covid-19 Full Text available with Trip Pro

Hydroxychloroquine with or without azithromycin in mild-to-moderate covid-19 CDEI - Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 — CDEI Open Menu Close Menu Open Menu Close Menu Jul 30 Written By Citation: Zampieri, F. G. , Rosa, R. G., Azevedo, L. C. P., Veiga, V. C., Avezum, A., . . . Berwanger, O. (2020). Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. New England Journal of Medicine . DOI: Full PICO and Limitations in text (...) : Population: 504 patients, age > 18 years old, hospitalized with confirmed Covid-19, 14 or fewer days since symptom onset, mild to moderate symptoms. Interventions and Comparator Interventions: 172 patients were randomized to receive 400mg hydroxychloroquine twice daily for 7 days plus 500mg azithromycin once a day in addition to standard of care. 159 patients were randomized to receive 400mg hydroxychloroquine twice daily for 7 days in addition to standard of care. Comparator: 173 patients were

2020 Covid-19 Drug Evidence Initiative

8. Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Full Text available with Trip Pro

Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians | Annals of Internal Medicine LOGIN TO YOUR ACCOUNT or Create a new account Email Can't sign in? Forgot your (...) practice points on the use of chloroquine or hydroxychloroquine alone or in combination with azithromycin for the prophylaxis or treatment of coronavirus disease 2019 (COVID-19) ( , ) from the living status. This decision was made in light of recent information on the topic. Three large, in-progress randomized controlled trials (RCTs) with strong study designs ceased enrollment for the hydroxychloroquine-only versus control comparison early due to lack of efficacy in preliminary analyses

2020 American College of Physicians

9. Effectiveness and Safety of Chloroquine or Hydroxychloroquine as a mono-therapy or in combination with Azithromycin in the treatment of COVID-19 patients: Systematic Review and Meta-Analysis Full Text available with Trip Pro

Effectiveness and Safety of Chloroquine or Hydroxychloroquine as a mono-therapy or in combination with Azithromycin in the treatment of COVID-19 patients: Systematic Review and Meta-Analysis Effectiveness and Safety of Chloroquine or Hydroxychloroquine as a mono-therapy or in combination with Azithromycin in the treatment of COVID-19 patients: Systematic Review and Meta-Analysis | medRxiv Search for this keyword Effectiveness and Safety of Chloroquine or Hydroxychloroquine as a mono-therapy (...) or in combination with Azithromycin in the treatment of COVID-19 patients: Systematic Review and Meta-Analysis Ramy Mohamed Ghazy , Abdallah Elmaghraby , Ramy Shaaban , Ahmed Kamal , Hatem Beshir , Amr Moursi , Ahmed Ramadan , Sarah Hamed N. Taha doi: https://doi.org/10.1101/2020.07.25.20162073 Ramy Mohamed Ghazy 1 Tropical Health Department, High Institute of Public Health, Alexandria University , Egypt Abdallah Elmaghraby 2 Department of Cardiology, Alexandria University , Egypt Ramy Shaaban 3 Department

2020 Cold Spring Harbor Laboratory

10. Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians Full Text available with Trip Pro

Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians | Annals of Internal Medicine LOGIN TO YOUR ACCOUNT or Create a new (...) , Worcester, Massachusetts (G.M.A.) , Portland Veterans Affairs Medical Center, Portland, Oregon (A.J.O.) , University of Pennsylvania, Philadelphia, Pennsylvania (M.A.F.) , University of Illinois College of Medicine, Urbana, Illinois (J.A.J.) , Oregon Health & Science University, Portland, Oregon (L.L.H.) , In this letter, we update the American College of Physicians' previous practice points about chloroquine or hydroxychloroquine alone or in combination with azithromycin for prophylaxis or treatment

2020 American College of Physicians

11. Azithromycin Treatment vs Placebo in Children With Respiratory Syncytial Virus-Induced Respiratory Failure: A Phase 2 Randomized Clinical Trial Full Text available with Trip Pro

Azithromycin Treatment vs Placebo in Children With Respiratory Syncytial Virus-Induced Respiratory Failure: A Phase 2 Randomized Clinical Trial Azithromycin Treatment vs Placebo in Children With Respiratory Syncytial Virus-Induced Respiratory Failure: A Phase 2 Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation JAMA Netw Open Actions . 2020 Apr 1;3(4):e203482. doi: 10.1001/jamanetworkopen.2020.3482. Azithromycin Treatment vs Placebo in Children With Respiratory Syncytial Virus-Induced Respiratory Failure: A Phase 2 Randomized Clinical Trial , , , , , , , Affiliations Expand Affiliations 1 Department of Pediatrics, University of Alabama at Birmingham. 2

2020 EvidenceUpdates

12. Should azithromycin be used to treat COVID-19? A rapid review Full Text available with Trip Pro

Should azithromycin be used to treat COVID-19? A rapid review Should Azithromycin Be Used to Treat COVID-19? A Rapid Review - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center for Biotechnology Information Show account info Close Account Logged in as: username (...) Actions . 2020 Jun 23;4(2):bjgpopen20X101094. doi: 10.3399/bjgpopen20X101094. Print 2020. Should Azithromycin Be Used to Treat COVID-19? A Rapid Review , Affiliations Expand Affiliations 1 GP and DPhil Student, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK Oghenekome.gbinigie@phc.ox.ac.uk. 2 Post-Doctoral Researcher, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. PMID: 32398343 DOI: Free article Item in Clipboard Should

2020 EvidenceUpdates

13. Effects of Hydroxychloroquine with or without Azithromycin on QT interval in COVID-19: A Systematic Review Full Text available with Trip Pro

Effects of Hydroxychloroquine with or without Azithromycin on QT interval in COVID-19: A Systematic Review Effects of Hydroxychloroquine with or without Azithromycin on QT interval in COVID-19: A Systematic Review - Authorea "); } "); } "); } "); } "); } "); } "); } AUTHOREA loading page this is for holding javascript data Effects of Hydroxychloroquine with or without Azithromycin on QT interval in COVID-19: A Systematic Review +2 Siddharth Shah , Kuldeep Shah , Mohit turagam , Dhanunjaya (...) Lakkireddy , Jalaj Garg Siddharth Shah State University of New York Upstate Medical University Kuldeep Shah West Virginia University Mohit turagam Icahn School of Medicine at Mount Sinai Dhanunjaya Lakkireddy The Kansas City Heart Rhythm Institute (KCHRI) @ HCA MidWest Jalaj Garg Medical College of Wisconsin Abstract Introduction: Hydroxychloroquine (HCQ) alone or in combination with azithromycin (AZ) is one of the many therapies being explored for the treatment of Coronavirus 2019 (COVID-19). We

2020 Authorea, Inc.

14. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. Full Text available with Trip Pro

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. Hydroxychloroquine, with or without azithromycin, has been considered as a possible therapeutic agent for patients with coronavirus disease 2019 (COVID-19). However, there are limited data on efficacy and associated adverse events.To describe the association between use of hydroxychloroquine, with or without azithromycin, and clinical outcomes among hospital (...) follow-up was April 24, 2020.Receipt of both hydroxychloroquine and azithromycin, hydroxychloroquine alone, azithromycin alone, or neither.Primary outcome was in-hospital mortality. Secondary outcomes were cardiac arrest and abnormal electrocardiogram findings (arrhythmia or QT prolongation).Among 1438 hospitalized patients with a diagnosis of COVID-19 (858 [59.7%] male, median age, 63 years), those receiving hydroxychloroquine, azithromycin, or both were more likely than those not receiving either

2020 JAMA

15. Covid-19: New data on the cardiac adverse effects of the combination of hydroxychloroquine (Plaquenil) with azithromycin (Zithromax or other brands) Full Text available with Trip Pro

Covid-19: New data on the cardiac adverse effects of the combination of hydroxychloroquine (Plaquenil) with azithromycin (Zithromax or other brands) Prescrire IN ENGLISH - Spotlight ''New data on the cardiac adverse effects of the combination of hydroxychloroquine (Plaquenil°) with azithromycin (Zithromax° or other brands)'', 16 April 2020 {1} {1} {1} | | > > > New data on the cardiac adverse effects of the combination of hydroxychloroquine (Plaquenil°) with azithromycin (Zithromax° or other (...) brands) Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight New data on the cardiac adverse effects of the combination of hydroxychloroquine (Plaquenil°) with azithromycin (Zithromax° or other brands) NEWS UPDATE As of mid-April 2020, more and more clinical data are confirming that the combination of hydroxychloroquine (Plaquenil°) with azithromycin

2020 Prescrire

16. Covid-19 drug vignettes: Azithromycin

Covid-19 drug vignettes: Azithromycin Drug vignettes: Azithromycin - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Drug vignettes: Azithromycin May 13, 2020 Robin E Ferner*, Jeffrey K Aronson On behalf of the Oxford COVID-19 Evidence Service Team Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences University of Oxford *University of Birmingham Correspondence (...) to Description of the drug, including regulatory status Azithromycin is a macrolide antibacterial drug, derived from erythromycin, licensed in the and in the , and used to treat bacterial infections. It has been used in combination with hydroxychloroquine in the treatment of COVID-19. However, there is an adverse drug–drug interaction between the two, which contraindicates their combined use. Mechanism of action Azithromycin exerts its antibacterial action by binding to the RNA of susceptible organisms

2020 Oxford COVID-19 Evidence Service

17. Hydroxychloroquine with or without azithromycin for COVID-19

Hydroxychloroquine with or without azithromycin for COVID-19 Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca March 30 (...) , 2020 COVID-19 Rapid Reviews Along with regular Tools for Practice, the PEER team will be writing rapid reviews to address COVID-19 topics relevant for primary care. The evidence is changing rapidly and it is possible that as you read this, new evidence will already be available. We will try our best to stay in front and keep you up-to- date during these challenging times. Hydrochloroquine with or without azithromycin for COVID-19 Clinical Question: Is hydroxychloroquine (with or without

2020 Tools for Practice

18. Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19

Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19 Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19 - American College of Cardiology ') Search All Types Search or Menu and use of hydroxychloroquine and chloroquine in clinical practice are outlined below. Hydroxychloroquine or chloroquine therapy should occur in the context of a clinical trial or registry, until sufficient evidence is available for use in clinical (...) of hydroxychloroquine or chloroquine for pandemic research; suggestions for researchers are outlined . In vitro and preliminary clinical research have suggested that hydroxychloroquine alone and in combination with azithromycin could prove to be an effective treatment for COVID-19. A small study in France enrolling 26 treated patients and 16 non-randomized controls showed that hydroxychloroquine alone or in combination with azithromycin shortened the time to resolution of viral shedding of COVID-19. 1 Based

2020 American College of Cardiology

19. Efficacy of Azithromycin 1% and 1.5% ophthalmic solutions compared to tobramycin 0.3% eye drops: A systematic review and meta-analysis Full Text available with Trip Pro

Efficacy of Azithromycin 1% and 1.5% ophthalmic solutions compared to tobramycin 0.3% eye drops: A systematic review and meta-analysis Efficacy of Azithromycin 1% and 1.5% ophthalmic solutions compared to tobramycin 0.3% eye drops: A systematic review and meta-analysis | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting (...) preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article Efficacy of Azithromycin 1% and 1.5% ophthalmic solutions compared to tobramycin 0.3% eye drops: A systematic review and meta-analysis Birhanu Motbaynor, Teshager Worku Kassie Birhanu Motbaynor Haramaya University College of Health and Medical Sciences Corresponding Author ORCiD

2020 Research Square

20. Statistical review of Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Statistical review of Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial application/octet-stream

2020 Covid-19 Ad hoc papers